Search research articles
Contact Us
Filters
Showing results (121-130 of 215) with videos related to
Page
of 22
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
December 16, 2014
Real-life experience of a brief arsenic trioxide-based consolidation chemotherapy in the management of acute promyelocytic leukemia: favorable outcomes with limited anthracycline exposure and shorter consolidation therapy
Mindy Leech, Lawrence Morris, Moishe Stewart, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 13, 2010
NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromes
Peter L Greenberg, Cynthia K Rigsby, Richard M Stone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2008
Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features
Judith E Karp, B Douglas Smith, Ivana Gojo, et al.
JNCI Cancer Spectrum
|
July 31, 2019
Association Between Ownership of Imaging Equipment and Appropriateness of Staging Positron-Emission Tomography in Non-Hodgkin Lymphoma
Scott F Huntington, Weiwei Zhu, Jessica R Hoag, et al.
British Journal of Haematology
|
January 29, 2014
Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes
John F Seymour, John M Bennett, Alan F List, et al.
Critical Reviews in Oncology/Hematology
|
May 11, 2010
Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes
John F Seymour, Pierre Fenaux, Lewis R Silverman, et al.
Cancer
|
September 15, 2018
Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma
Scott F Huntington, Jessica R Hoag, Weiwei Zhu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 21, 2010
Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia
Steven D Gore, Ivana Gojo, Mikkael A Sekeres, et al.
British Journal of Haematology
|
April 10, 2014
Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes
Amer M Zeidan, Ju-Whei Lee, Thomas Prebet, et al.
Leukemia & Lymphoma
|
October 2, 2019
Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents
Amer M Zeidan, Xin Hu, Weiwei Zhu, et al.
Page
of 22
Search research articles
Search
Showing results (121-130 of 215) with videos related to
Sort By:
Page
of 22
Clinical Lymphoma, Myeloma & Leukemia
|
December 16, 2014
Real-life experience of a brief arsenic trioxide-based consolidation chemotherapy in the management of acute promyelocytic leukemia: favorable outcomes with limited anthracycline exposure and shorter consolidation therapy
Mindy Leech, Lawrence Morris, Moishe Stewart, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 13, 2010
NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromes
Peter L Greenberg, Cynthia K Rigsby, Richard M Stone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2008
Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features
Judith E Karp, B Douglas Smith, Ivana Gojo, et al.
JNCI Cancer Spectrum
|
July 31, 2019
Association Between Ownership of Imaging Equipment and Appropriateness of Staging Positron-Emission Tomography in Non-Hodgkin Lymphoma
Scott F Huntington, Weiwei Zhu, Jessica R Hoag, et al.
British Journal of Haematology
|
January 29, 2014
Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes
John F Seymour, John M Bennett, Alan F List, et al.
Critical Reviews in Oncology/Hematology
|
May 11, 2010
Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes
John F Seymour, Pierre Fenaux, Lewis R Silverman, et al.
Cancer
|
September 15, 2018
Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma
Scott F Huntington, Jessica R Hoag, Weiwei Zhu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 21, 2010
Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia
Steven D Gore, Ivana Gojo, Mikkael A Sekeres, et al.
British Journal of Haematology
|
April 10, 2014
Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes
Amer M Zeidan, Ju-Whei Lee, Thomas Prebet, et al.
Leukemia & Lymphoma
|
October 2, 2019
Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents
Amer M Zeidan, Xin Hu, Weiwei Zhu, et al.
Page
of 22